Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-38721
Titel: Sacubitril/valsartan in heart failure : efficacy and safety in and outside clinical trials
VerfasserIn: Abdin, Amr
Schulz, Martin
Riemer, Uwe
Hadëri, Bledar
Wachter, Rolf
Laufs, Ulrich
Bauersachs, Johann
Kindermann, Ingrid
Vukadinović, Davor
Böhm, Michael
Sprache: Englisch
Titel: ESC Heart Failure
Bandnummer: 9
Heft: 6
Seiten: 3737-3750
Verlag/Plattform: Wiley
Erscheinungsjahr: 2022
Freie Schlagwörter: Heart failure
Sacubitril/valsartan
Efficacy
Effectiveness
Safety
Implementation
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Heart failure (HF) treatment has changed substantially over the last 30 years, leading to significant reductions in mortality and hospital admissions in patients with HF with reduced ejection fraction (HFrEF). Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve quality of life, mortality, and HF hospitalizations for patients with HFrEF. The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (S/V) has an important role in the treatment of patients with HFrEF. The PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) randomized controlled trial has established solid evidence for the treatment of HFrEF in various subgroups. Apart from HFrEF, several studies have been conducted using S/V in various indications: patients hospitalized with acute decompensated HF, HF with preserved ejection fraction, acute myocardial infarction with reduced ejection fraction, uncontrolled and resistant hypertension, and chronic kidney disease. Data from the German Institute for Drug Use Evaluation reveal that implementation of S/V has increased steadily over time and, by the end of 2021, an estimated 266 000 patients were treated with S/V in Germany. The estimated cumulative real-world patient exposure is >5.5 million patient-treatment years worldwide. The number of patients treated with S/V largely exceeds the number of patients treated in clinical trials, and the current indication for S/V is larger than the strict inclusion/exclusion criteria of the randomized trials. Especially elderly patients, women, and patients with more and more severe comorbidities are underrepresented in the clinical trials. We therefore aimed to summarize the importance of S/V in HF in terms of efficacy and safety in clinical trials and daily clinical practice.
DOI der Erstveröffentlichung: 10.1002/ehf2.14097
URL der Erstveröffentlichung: https://doi.org/10.1002/ehf2.14097
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-387219
hdl:20.500.11880/34895
http://dx.doi.org/10.22028/D291-38721
ISSN: 2055-5822
Datum des Eintrags: 17-Jan-2023
Bezeichnung des in Beziehung stehenden Objekts: Supporting Information
In Beziehung stehendes Objekt: https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fehf2.14097&file=ehf2_14097-sup-0001-Supp.+PubMed+search+strategy_20220224.docx
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Innere Medizin
Professur: M - Prof. Dr. Michael Böhm
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes



Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons